Pharmaceuticals Government Tenders in United States

Registration, quality assurance and the shape of a medicines contract

A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programmes -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.

Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.

The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and programme funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.

This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.

Who buys pharmaceuticals in United States?

GlobalGov holds 3,151 pharmaceuticals records from 263 distinct buying organisations in United States. The most frequent publishers are National Institutes Of Health (362 records); DLA Troop Support (217 records); Network Contract Office 23 (36C263) (79 records); 262-Network Contract Office 22 (36C262) (71 records); 250-Network Contract Office 10 (36C250) (62 records); Substance Abuse And Mental Health Services Adminis (61 records). Between them the 6 largest account for 27% of everything published, so buying here is spread across many separate authorities.

What are pharmaceuticals contracts worth in United States?

394 of the 3,151 records publish a contract value. The median is $440,370 and the largest single published value is $26.4B. By size, 130 under $100k, 98 between $100k and $1M, 81 between $1M and $10M, 85 above $10M. The remaining 2,757 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.

How long do bidders get to respond to pharmaceuticals tenders in United States?

Across the 2,652 United States pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 10 days. A quarter of them allowed 7 days or fewer and a quarter stayed open for more than 16. 1,315 of them (50%) closed within a fortnight of being published, so on this market a bidder who reviews notices once a week can lose most of the response window before reading one.

How often are pharmaceuticals tenders published in United States?

United States publishes about 186 notices a month in this category, 2,234 in the last twelve months. That is 1931% more than the 110 published in the twelve months before that. Over the last three years there were 2,394, spread across 195 separate months of activity since 24 March 2006. April is historically the busiest month. The most recent was published 30 September 2026.

How does United States compare with other pharmaceuticals markets?

Among the 39 countries where GlobalGov holds a comparable pharmaceuticals market, United States ranks 2nd by number of records. The largest is Germany (4,115 records against 3,151 here). Within United States itself, pharmaceuticals is the 13th largest of the 85 procurement categories tracked here.

Where do the United States pharmaceuticals records on this page come from?

These 3,151 records are collected from 4 official sources: SAM.gov (2,337), Grants.gov (747), Simpler.Grants.gov (56), USAspending (11). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-10-01.

Open Pharmaceuticals tenders in United States

Showing 10 of the 132 notices open in this category today. Openness uses the same definition as the United States market page: active, not marked awarded, cancelled, closed or expired, and either closing in the future or published within the last 90 days with no stated closing date.

Other procurement categories in United States

Pharmaceuticals procurement in other markets